Risk factor
Low price volatility
Profitability factor
Excellent dividends
About
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, and Other Business Unit segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre names for anti-cancer and supplementary treatments. The company provides anti-infection drugs under the Brosym, Colimycin, Cubicin, Lipo-AB, Agrippal, Cepiro, Flusine, Maxtam, Metacin, and Flucelvax names for anti-infection and flu. In addition, it offers healthcare related drugs under the Algitab, Alginos, Alginos Fresh, Bio-Cal Plus, and Sulfin names for digest system, osteoporosis, and metabolism. Further, the company engages in the selling functional foods; and import and export trading and investment activities. The company was incorporated in 1960 and is headquartered in Taipei, Taiwan.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, of fair va
Target Price
The average target price of 4105.TWO is 86 and suggests 18% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell